Monoclonal antibody MOC-31-In-111

Drug Profile

Monoclonal antibody MOC-31-In-111

Alternative Names: 111-In-DTPA-MOC-31

Latest Information Update: 19 Sep 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 19 Sep 2001 No-Development-Reported for Cancer in Netherlands (IV-injection)
  • 15 May 1997 New profile
  • 15 May 1997 Investigation in Cancer in Netherlands (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top